IJBPAS, September, 2024, 13(9): 4388-4396

ISSN: 2277–4998

International Journal of Biology, Pharmacy and Allied Sciences (IJBPAS)

'A Bridge Between Laboratory and Reader'

www.ijbpas.com

ARTIFICIAL INTELLIGENCE (AI) IN REGULATORY APPROVAL PROCESS

GHOSH R, SUDHEER KUMAR T*, KAMARAJ R

Department of Pharmaceutical Regulatory Affairs, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur-603203, Chengalpattu, Tamil Nadu, India

***Corresponding Author: Mr. T. Sudheer Kumar: E Mail: tirumals@srmist.edu.in**

Received 18th July 2023; Revised 20th Sept. 2023; Accepted 2nd Dec. 2023; Available online 1st Sept. 2024

https://doi.org/10.31032/IJBPAS/2024/13.9.8305

ABSTRACT

The integration of Artificial Intelligence (AI) in the regulatory approval process has emerged as a transformative paradigm, revolutionizing industries and institutions worldwide. This abstract provides an overview of the multifaceted impact of AI on regulatory approval procedures across diverse sectors. AI technologies, encompassing machine learning, natural language processing, and data analytics, have streamlined and expedited the regulatory landscape. They enable efficient analysis of vast data sets, facilitating more informed decision-making by regulatory agencies. AI-driven predictive models assess risks, forecast outcomes, and identify potential safety concerns in pharmaceuticals, medical devices, and food products. These capabilities enhance the assessment of product efficacy and safety profiles, leading to more accurate, evidence-based approvals. Furthermore, AI augments regulatory compliance and monitoring efforts. It enables real-time surveillance of adverse events and anomalous patterns, ensuring timely interventions and mitigating risks. Automated compliance checks, powered by AI algorithms, enhance the scrutiny of submissions and adherence to regulatory guidelines. However, challenges related to data privacy, algorithmic transparency, and bias mitigation must be vigilantly addressed to maintain integrity and fairness in the decision-making process. The infusion of AI into regulatory approval processes marks a pivotal advancement with profound implications. By enhancing data-driven decision-making, improving compliance monitoring, and redefining stakeholder interactions, AI accelerates the pace and precision of regulatory approvals. While challenges persist, the judicious

incorporation of AI holds the potential to usher in a new era of efficacy, safety, and accessibility across industries that are subject to regulatory oversight.

Keywords: Artificial Intelligence (AI), Regulatory Approval, Regulatory Affairs

INTRODUCTION

Artificial intelligence (AI), often known as machine intelligence, is the emulation of human intelligence functions by machines, particularly computer systems. It entails the development of algorithms and models that let computers to carry out operations like problem-solving, reasoning, learning, perception, language understanding, and decision-making that ordinarily need human intelligence. The goal of AI technology is to make it possible for machines to reproduce cognitive processes and human-like behaviour in a variety of contexts **[20]**.

AI has many applications in many different sectors, including:



Figure 1: Applications of AI in different sectors

Even though AI has come a long way, there are still issues to be aware of, including potential job loss, moral quandaries, and the need for responsible development. AI has the potential to spur enormous improvements and change many facets of our daily lives as it develops **[20]**.

With the incorporation of Artificial Intelligence (AI) technology, the area of pharmaceutical regulatory concerns has seen a significant development in recent years. AI has emerged as a formidable tool that can alter the way regulatory procedures are managed, speeding up drug development timelines, improving compliance, and

assuring patient safety as the pharmaceutical industry continues to change and adapt to new problems **[9]**. The journey from drug discovery to market approval is being reshaped by AI-driven innovations that automate tasks, analyse complex data, predict outcomes, and ultimately usher in a new era of efficiency and effectiveness. This introduction delves into the intersection of AI and pharmaceutical regulatory affairs **[19]**.

Importance of AI in the regulatory approval process

AI will have a significant impact on how the drug review process develops. Large datasets can include patterns that humans would struggle to identify. AI can do this. Technologies utilizing artificial intelligence (AI) in regulatory affairs can help to expedite the review process, enabling novel pharmaceuticals to reach the market more quickly **[22]**. Although the use of AI in medication regulatory problems is still in its early stages, many businesses are beginning to adopt this technology, suggesting that usage will increase over time **[16]**.

The use of artificial intelligence (AI) in regulatory affairs may aid the pharmaceutical industry in several ways, including:

- It can be used for quicker and more accurate reviews of new medications;
- It can identify adverse events early on and provide initial warning signals;
- It may assist with data mining;
- It can increase efficiency generally.

Application of AI in regulatory approval process

1. **Labelling**: Health agencies will increasingly adopt AI in labelling and regulatory affairs. Machine learning will enable AI to comprehend labels, suggest corrections, and identify errors. AI's role extends to gauging public perceptions and improving marketing strategies, aiding corporations in better understanding medicines and enhancing outreach materials.
2. **Regulatory Publishing**: AI's widespread use will reshape regulatory publishing by automating XML-based drug information dissemination and submission to agencies like the FDA. This labour-intensive process will see efficiency gains through AI-driven automated hyperlinking and bookmarking, facilitated by machine learning advancements.
3. **Regulatory submissions:** AI streamlines regulatory filing, cutting costs and time for pharmaceutical firms. Automation curbs resource-

intensive compliance spending. Mundane tasks are efficiently handled, such as generating regulatory documents from templates or extracting clinical study data.

4. **Data analysis and pattern recognition**: AI excels in vital tasks: analysing clinical trial and real-world data for safety signals in regulations. Machine learning detects nuanced patterns and links that human reviewers might overlook, enhancing comprehensive safety assessments.
5. **Natural Language Processing (NLP):** AI-driven NLP makes it possible to analyse complicated regulatory documents like medicine labels, safety reports, and scientific literature in an effective manner. NLP algorithms can extract key facts from unstructured data, enabling quicker review procedures and guaranteeing that crucial insights are not overlooked.
6. **Predictive modelling:** By concentrating on items with potential concerns or those with promising safety profiles, AI-powered predictive modelling helps concentrate regulatory resources. Regulatory agencies can speed up the approval of safe and effective products by streamlining the review procedure, improving patient access to cutting-edge therapies.
7. **Post-Marketing Surveillance:** Once a product is on the market, AI enables ongoing monitoring of it. AI systems can analyse real-world data to identify new safety issues and enable quick regulatory action, improving public safety.

AI will speed up the evaluation process for developing new drugs and hastening their introduction to the market in regulatory issues. The application of AI in medication regulatory matters is still in its early stages, but as more businesses use this technology, it is likely to become more prevalent **[13]**.

Impact of AI on the regulatory review process

The regulatory review process has been significantly impacted by artificial intelligence (AI), which has completely changed how pharmaceutical businesses and regulatory bodies approach drug approval. AI has made major improvements throughout the regulatory review process that improve efficiency, accuracy, and decision-making **[18]**.

Several revolutionary effects could result from the inclusion of AI in the regulatory assessment process:

1. **Faster and More Efficient Reviews:** AI can greatly cut down on the amount of time needed to review

regulatory submissions. The review process is sped up by automation of repetitive processes and enhanced data analysis, allowing for quicker approvals and prompt patient access to novel medicines **[15]**.

2. **Improved Safety Assessment:** AI's capacity to recognize danger signs and potential negative outcomes improves the general safety evaluation of items. AI can reveal previously unknown dangers through the analysis of enormous volumes of data, resulting in better regulatory judgments **[5]**.
3. **Enhanced Decision-Making:** Regulatory bodies can focus their efforts on items that need closer examination by using data-driven decisions made possible by AI-powered predictive modelling. This strategy improves resource management and makes it possible for better risk management **[16]**.

Countries using AI in regulatory approval process

Certain nations might provide fast approval pathways for specific medications, which might greatly shorten the approval period for medicines that treat serious unmet medical needs. Always check with the relevant regulatory organizations for the most precise and recent information on when a medicine will be approved in a certain nation **[8]**.

Table 1: Countries using AI in approval process with their general without AI and estimated timespan after using AI

Sl. No.	Countries using AI in regulatory review process	Regulatory Agencies of the country	General time span for drug approval without using AI (months)	Estimated time span for drug approval after using AI (months)
1	United States	FDA (Food and Drug Administration)	9	6
2	Europe	EMA (European Medicines Agencies)	15	12
3	India	CDSCO (Central Drug Standard Control Organization)	24	18
4	United Kingdom	MHRA (Medicines and Healthcare products Regulatory Agency)	9	6
5	Japan	PMDA (Pharmaceutical and Medical Devices Agency)	15	12
6	Australia	TGA (Therapeutic Goods Agency)	12	7
7	Canada	Health Canada	15	13
8	China	NMPA (National Medicinal Products Administration)	18	12

Benefits of using Artificial Intelligence

1. **Automation:** Artificial intelligence (AI) can automate routine processes, lowering the need for manual labour and freeing up human resources for more imaginative and strategic jobs.
2. **Effectiveness:** AI algorithms are significantly faster and more accurate than humans at processing and analysing vast amounts of data, which enables them to make decisions and solve problems more effectively.
3. **precision:** AI systems can carry out activities with a high degree of consistency and precision, which minimizes errors brought on by human variables like fatigue and distractions.
4. **Scalability:** Systems driven by AI are easily scalable to manage heavy workloads and vast data volumes without disproportionately increasing human effort.
5. **24/7 Availability:** AI-driven applications can work around the clock, offering assistance and services whenever needed, which is particularly useful for international companies and crucial services.
6. **Personalization:** AI makes it possible for experiences to be customised by analysing user behaviour and preferences to present relevant recommendations and content.
7. **Data analysis:** AI can find important insights and patterns in huge datasets, enabling organizations to make forecasts and decisions that are well-informed.
8. **Safety and stake Mitigation:** AI can be utilized in risky surroundings or circumstances when people's safety is at stake, reducing the amount of time that people are exposed to hazardous situations **[20]**.

Drawbacks of using Artificial Intelligence

1. **Job Replacement:** One of the biggest worries is the possibility that AI would replace some jobs, which would cause unemployment in particular industries.
2. **Fairness and Bias:** AI systems can provide unfair or discriminatory results by inheriting biases from their training data, especially in touchy areas like hiring, lending, and criminal justice.
3. **Lack of Creativity and Intuition:** Human creativity, intuition, and empathy—which are crucial in many decision-making processes—cannot be replicated by AI.
4. **Dependability and Reliability:** Over-relying on AI can cause problems when the system malfunctions or renders inaccurate

judgments, particularly in crucial applications like autonomous vehicles or healthcare.

5. **Privacy Issues:** Because AI can handle and analyse massive volumes of data, privacy issues and the possibility of sensitive data being misused are raised.
6. **Complexity and Upkeep:** Creating and keeping up-to-date AI systems can be time- and resource-consuming, requiring specialized knowledge.
7. **Ethical Conundrums:** As AI technology advances, ethical concerns regarding the possible repercussions of giving computers extraordinary intellect, autonomy, and decision-making abilities arise.
8. **Unpredictability:** Deep learning-based AI systems, in particular those that are highly sophisticated, can occasionally yield findings that are hard to understand or explain, which leads in a lack of transparency in decision-making **[12]**.

While AI offers numerous benefits that can transform industries and improve efficiency, it also comes with several drawbacks that need to be carefully managed. Striking a balance between harnessing AI's capabilities and addressing its limitations is crucial for its responsible and ethical use **[20]**.

Current obstacles and challenges to AI adoption

AI success relies on available training data, which must be trustworthy and of high quality. Accessing data can lead to costs, and obstacles to AI adoption in pharmaceuticals include personnel shortages, funding gaps for small businesses, job displacement fears, scepticism about AI data, and the "black box" challenge. Some pharmaceutical roles will be automated with "narrow AI," requiring substantial data for specific tasks. Human involvement remains crucial for AI's effective design and use, despite its ability to replace routine jobs. The worry of unemployment due to AI might be exaggerated. Pharma firms seek clarity on AI's problem-solving and set achievable goals. Leveraging AI requires skilled data scientists, AI-aware software engineers, and alignment with business and R&D objectives **[1]**.

CONCLUSION

AI integration has revolutionized regulatory affairs, enhancing medication approval efficiency, accuracy, and innovation. Regulatory bodies and pharmaceutical firms utilize AI, including ML algorithms, for streamlined processes, quicker decisions, and optimal resource allocation. These AI-driven solutions expedite drug development, safety assessment, and post-market monitoring, leading to improved decision-making and faster time-to-market **[20]**.

Globally, the FDA, EMA, and even developing nations like China and India leverage AI to enhance evaluation and safety monitoring. However, challenges related to transparency and accountability remain. Collaboration between regulators, industry, and AI experts becomes crucial for unbiased assessments, data privacy, and framework establishment **[2]**.

Incorporating AI in regulations poses challenges of accountability, transparency, and interpretability. Robust frameworks require regulator-industry collaboration to assess models, counter bias, and ensure privacy while adhering to diverse data laws. Global regulators must engage with AI experts to stay updated on progress, fostering a dynamic relationship that enhances drug approval processes and maintains rigor amid pharmaceutical changes **[11]**.

Balancing AI's potential with stringent regulation ensures safer and more accessible medicines worldwide, shaping the future landscape of medication approvals. By navigating these challenges, AI augments medicine safety, access, and regulatory integrity, ultimately benefiting patients worldwide **[12]**.

REFERENCES

[1] Abbott, R., & Sarch, A. F. (2019). Punishing artificial intelligence: legal fiction or science fiction.

[2] Ahluwalia, K. (2022). The future of CMC regulatory submissions: streamlining activities using structured content and data management. *Journal of Pharmaceutical Sciences*.

[3] Bajwa, J., Munir, U., Nori, A., & Williams, B. (2021). Artificial intelligence in healthcare: Transforming the practice of medicine. *Future Healthcare Journal, 8*, e188–e194.

[4] Bostrom, N. (n.d.). *Superintelligence*.

[5] Chan, H. C. S., *et al*. (2019). Advancing drug discovery via artificial intelligence. *Trends in Pharmacological Sciences, 40*(8), 592–604.

[6] Chen, M., & Decary, M. (2020). Artificial intelligence in healthcare: An essential guide for health leaders. *Healthcare Management Forum*.

[7] EMA - European Medicines Agency. Available at: https://www.ema.europa.eu/

[8] European Commission. (2020). White Paper on Artificial Intelligence: A European Approach to Excellence and Trust. Available at: https://ec.europa.eu/info/sites/default/files/commission-white-paper-

artificial-intelligence-feb2020_en.pdf

[9] FDA - U.S. Food and Drug Administration. Available at: https://www.fda.gov/

[10] Health Canada. Available at: https://www.canada.ca/en/health-canada.html

[11] Howard, J. (2019). Artificial intelligence: implications for the future of work. *American Journal of Industrial Medicine*.

[12] Jacobs, A. Z., & Mulligan, D. K. (2022). The hidden governance in AI.

[13] M AG. (2021). Creating efficiencies in the extraction of data from randomized trials: a prospective evaluation of a machine learning and text mining tool. *BMC Medical Research Methodology, 21*(1).

[14] MHRA - Medicines and Healthcare Products Regulatory Agency. Available at: https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency

[15] Miles, J., & Walker, A. (2006). The potential application of artificial intelligence in transport. *IEE Proceedings-Intelligent Transport Systems, 153*, 183–198.

[16] Paul, D., *et al*. (2021). Artificial intelligence in drug discovery and development. *Drug Discovery Today*.

[17] PMDA - Pharmaceuticals and Medical Devices Agency (Japan). Available at: https://www.pmda.go.jp/english/

[18] Ramesh, A. (2004). Artificial intelligence in medicine. *Annals of The Royal College of Surgeons of England, 86*, 334–338.

[19] Rich, E., Knight, K., & Nair, S. B. (2010). *Artificial Intelligence* (3rd ed.). Tata McGraw Hill India.

[20] Russell, S. J., & Norvig, P. (2021). *Artificial Intelligence: A Modern Approach* (4th ed.). Pearson.

[21] TGA - Therapeutic Goods Administration (Australia). Available at: https://www.tga.gov.au/

[22] Wirtz, B. W. (2019). Artificial intelligence and the public sector—applications and challenges. *International Journal of Public Administration, 42*, 596–615.